| Q37920360 | 15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy |
| Q82905603 | A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib |
| Q24546366 | Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity |
| Q57796537 | Activation of KRAS mediates resistance to targeted therapy in MET ex on 14 mutant non-small cell lung cancer |
| Q36822111 | Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer |
| Q43652201 | Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/- mice |
| Q24633986 | An overview of the c-MET signaling pathway |
| Q33693109 | Antisense--time to shoot the messenger |
| Q38771978 | C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives. |
| Q38125434 | Cell-Autonomous and Non–Cell-Autonomous Mechanisms of HGF/MET–Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective |
| Q41251561 | Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma |
| Q84584265 | Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib |
| Q34494731 | Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression |
| Q54660009 | Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentation towards papillary carcinoma. |
| Q83903141 | Diosgenin Suppresses Hepatocyte Growth Factor (HGF)-Induced Epithelial–Mesenchymal Transition by Down-regulation of Mdm2 and Vimentin |
| Q37175416 | Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis |
| Q34782774 | Drug development of MET inhibitors: targeting oncogene addiction and expedience |
| Q36323379 | GDNF promotes tubulogenesis of GFRalpha1-expressing MDCK cells by Src-mediated phosphorylation of Met receptor tyrosine kinase |
| Q47833619 | Genetic alterations in human epithelial thyroid tumours |
| Q34303041 | Genetic markers in thyroid neoplasia |
| Q39819780 | HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells |
| Q37502372 | INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models |
| Q37403891 | In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer |
| Q38976616 | Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence |
| Q28253680 | Invasive growth: a MET-driven genetic programme for cancer and stem cells |
| Q87826971 | MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy |
| Q36089948 | MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome |
| Q89603062 | MET targeting: time for a rematch |
| Q38675350 | MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. |
| Q34085432 | Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression |
| Q38683133 | Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases |
| Q34236194 | Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis |
| Q28235183 | Met, metastasis, motility and more |
| Q39322020 | MiR-410 regulates MET to influence the proliferation and invasion of glioma |
| Q61417351 | MiRNAs in Malignant Melanoma |
| Q74100664 | Molecular basis of epithelial thyroid tumorigenesis |
| Q36299916 | Molecular classification and biomarker discovery in papillary thyroid carcinoma |
| Q35094749 | Molecular pathobiology of thyroid neoplasms |
| Q35208510 | Molecular pathogenesis of thyroid cancer |
| Q44004710 | Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece |
| Q33864524 | New treatment modalities in advanced thyroid cancer |
| Q43201388 | Non-autocrine, constitutive activation of Met in human anaplastic thyroid carcinoma cells in culture |
| Q38846778 | PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells. |
| Q73816410 | PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS |
| Q36626127 | Papillary carcinoma of the thyroid: methylation is not involved in the regulation of MET expression |
| Q36430189 | Pathogenetic mechanisms in thyroid follicular-cell neoplasia |
| Q38782345 | Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma. |
| Q46170165 | Prognostic significance of c-Met expression in glioblastomas |
| Q39901958 | RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation |
| Q47769312 | RETRACTED: Hepatocyte Growth Factor-Induced Expression of Ornithine Decarboxylase, c-met,and c-mycIs Differently Affected by Protein Kinase Inhibitors in Human Hepatoma Cells HepG2 |
| Q37002770 | Resistance of papillary thyroid cancer stem cells to chemotherapy |
| Q45143173 | Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis. |
| Q37730020 | Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers |
| Q39385631 | Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor |
| Q58164852 | Silencing the MET oncogene leads to regression of experimental tumors and metastases |
| Q44283525 | Study of MET protein levels and MET gene copy number in 72 sinonasal intestinal-type adenocarcinomas |
| Q33943764 | Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase |
| Q37539304 | Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors |
| Q37792116 | Targeting the MET oncogene in cancer and metastases. |
| Q41954928 | The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth |
| Q50977867 | The Pathogenetic Role of the HGF/c-Met System in Papillary Carcinoma of the Thyroid |
| Q38824065 | The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer |
| Q33922881 | The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. |
| Q55070676 | [Thirty years of Met receptor research: from the discovery of an oncogene to the development of targeted therapies]. |
| Q38923535 | c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma |